First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.

被引：14
|
作者：
Li, Zhigang
Sun, Yubei
Ye, Feng
Ma, Dong
Yin, Xianli
Zhuang, Wu
Yuan, Xianglin
Qin, Shukui
Zhang, Yiping
Gu, Kangsheng
Zhao, Kuaile
Xiao, Juxiang
Cheng, Ying
Bai, Yuxian
Luo, Suxia
Wang, Liwei
Wang, Cailian
Cui, Yi
Mei, Lingling
Shen, Lin
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
[2] Anhui Prov Hosp, Hefei, Anhui, Peoples R China
[3] Xiamen Univ, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China
[4] Guangdong Prov Peoples Hosp, Guangzhou, Guangdong, Peoples R China
[5] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[6] Fujian Canc Hosp, Fuzhou, Fujian, Peoples R China
[7] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan, Hubei, Peoples R China
[8] Jinling Hosp, PLA Canc Ctr Nanjing, Nanjing, Peoples R China
[9] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[10] Anhui Med Univ, Affiliated Hosp 1, Hefei, Anhui, Peoples R China
[11] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[12] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaaxi, Peoples R China
[13] Jilin Canc Hosp, Changchun, Peoples R China
[14] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[15] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[16] Jiaotong Univ, Sch Med, Renji Hosp Shanghai, Shanghai, Peoples R China
[17] Southeast Univ, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China
[18] MSD China, Shanghai, Peoples R China
[19] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4049
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
    Kato, K.
    Sun, J-M.
    Shah, M. A.
    Enzinger, P. C.
    Adenis, A.
    Doi, T.
    Kojima, T.
    Metges, J-P.
    Li, Z.
    Kim, S-B.
    Cho, B. C. Chul
    Mansoor, W.
    Li, S-H.
    Sunpaweravong, P.
    Maqueda, M. A.
    Goekkurt, E.
    Liu, Q.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1192 - S1193
  • [2] Q-TWiST analysis for pembrolizumab plus chemotherapy versus chemotherapy as first-line treatment for patients with advanced esophageal cancer in the KEYNOTE-590 study
    Diez Garcia, M.
    Shah, S.
    Joo, S.
    Valderrama, A.
    Zhang, S.
    Zhang, Y.
    Enzinger, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S348 - S348
  • [3] First-line pembrolizumab plus chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
    Kojima, Takashi
    Hara, Hiroki
    Tsuji, Akihito
    Yasui, Hisateru
    Muro, Kei
    Satoh, Taroh
    Ogata, Takashi
    Ishihara, Ryu
    Goto, Masahiro
    Baba, Hideo
    Nishina, Tomohiro
    Han, Shirong
    Sakata, Tomoko
    Yatsuzuka, Naoyoshi
    Doi, Toshihiko
    Kato, Ken
    ESOPHAGUS, 2022, 19 (04) : 683 - 692
  • [4] Pembrolizumab plus Chemotherapy as First-Line Treatment in advanced Oesophageal Cancer (KEYNOTE-590)
    Hartmann, Milan
    Zander, Thomas
    Alakus, Hakan
    ONKOLOGE, 2022, 28 (05): : 436 - 437
  • [5] First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
    Takashi Kojima
    Hiroki Hara
    Akihito Tsuji
    Hisateru Yasui
    Kei Muro
    Taroh Satoh
    Takashi Ogata
    Ryu Ishihara
    Masahiro Goto
    Hideo Baba
    Tomohiro Nishina
    Shirong Han
    Tomoko Sakata
    Naoyoshi Yatsuzuka
    Toshihiko Doi
    Ken Kato
    Esophagus, 2022, 19 : 683 - 692
  • [6] KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
    Kato, Ken
    Shah, Manish A.
    Enzinger, Peter
    Bennouna, Jaafar
    Shen, Lin
    Adenis, Antoine
    Sun, Jong-Mu
    Cho, Byoung Chul
    Ozguroglu, Mustafa
    Kojima, Takashi
    Kostorov, Vladimir
    Hierro, Cinta
    Zhu, Ying
    McLean, Lee Anne
    Shah, Sukrut
    Doi, Toshihiko
    FUTURE ONCOLOGY, 2019, 15 (10) : 1057 - 1066
  • [7] Pembrolizumab and Chemotherapy Combination as a First-line Treatment in Patients with advanced Oesophageal Cancer (KEYNOTE-590)
    Hartmann, Milan
    Zander, Thomas
    Alakus, Hakan
    ONKOLOGIE, 2022, 28 (05): : 436 - 437
  • [8] Advanced Esophageal Cancer: Pembrolizumab plus Chemotherapy as First-line Therapy
    Franke, Katharina
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (12): : 1255 - +
  • [9] Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer
    Kato, K.
    Shah, M. A.
    Enzinger, P. C.
    Bennouna, J.
    Shen, L.
    Adenis, A.
    Sun, J-M.
    Cho, B. C.
    Ozguroglu, M.
    Kojima, T.
    Kostorov, V.
    Hierro, C.
    Zhu, Y.
    Shah, S.
    Bhagia, P.
    Doi, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Wang, Hao-Lun
    Wang, Ying-Yuan
    Chen, Ze-Chang
    Zhou, Qin
    Li, Xiang-Ping
    Zhang, Ying-Ying
    CANCER MEDICINE, 2023, 12 (05): : 6182 - 6189
12345